"Withholding Treatment" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Withholding or withdrawal of a particular treatment or treatments, often (but not necessarily) life-prolonging treatment, from a patient or from a research subject as part of a research protocol. The concept is differentiated from REFUSAL TO TREAT, where the emphasis is on the health professional's or health facility's refusal to treat a patient or group of patients when the patient or the patient's representative requests treatment. Withholding of life-prolonging treatment is usually indexed only with EUTHANASIA, PASSIVE, unless the distinction between withholding and withdrawing treatment, or the issue of withholding palliative rather than curative treatment, is discussed.
Descriptor ID |
D028761
|
MeSH Number(s) |
E02.760.952 N02.421.585.952
|
Concept/Terms |
Withholding Treatment- Withholding Treatment
- Treatment, Withholding
- Treatments, Withholding
- Withholding Treatments
- Cessation of Treatment
- Treatment Cessation
- Treatment Cessations
Withdrawing Treatment- Withdrawing Treatment
- Treatment, Withdrawing
- Treatments, Withdrawing
- Withdrawing Treatments
|
Below are MeSH descriptors whose meaning is more general than "Withholding Treatment".
Below are MeSH descriptors whose meaning is more specific than "Withholding Treatment".
This graph shows the total number of publications written about "Withholding Treatment" by people in this website by year, and whether "Withholding Treatment" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1994 | 2 | 2 | 4 |
1995 | 1 | 1 | 2 |
1996 | 3 | 1 | 4 |
1997 | 1 | 3 | 4 |
1998 | 0 | 2 | 2 |
1999 | 0 | 2 | 2 |
2000 | 0 | 1 | 1 |
2002 | 0 | 1 | 1 |
2003 | 1 | 1 | 2 |
2005 | 1 | 2 | 3 |
2006 | 1 | 2 | 3 |
2007 | 0 | 2 | 2 |
2008 | 2 | 0 | 2 |
2009 | 0 | 1 | 1 |
2010 | 2 | 0 | 2 |
2011 | 1 | 2 | 3 |
2012 | 3 | 0 | 3 |
2013 | 1 | 3 | 4 |
2014 | 2 | 3 | 5 |
2016 | 3 | 2 | 5 |
2017 | 5 | 2 | 7 |
2018 | 2 | 0 | 2 |
2019 | 6 | 2 | 8 |
2020 | 1 | 1 | 2 |
2021 | 1 | 2 | 3 |
2023 | 0 | 1 | 1 |
2024 | 1 | 2 | 3 |
To return to the timeline,
click here.
Below are the most recent publications written about "Withholding Treatment" by people in Profiles.
-
Discontinuation of maintenance therapy in multiple myeloma guided by multimodal measurable residual disease negativity (MRD2STOP). Blood Cancer J. 2024 10 07; 14(1):170.
-
End of life care in a level IV outborn neonatal intensive care unit. J Perinatol. 2024 Jul; 44(7):1022-1028.
-
Hospital Policy Variation in Addressing Decisions to Withhold and Withdraw Life-Sustaining Treatment. Chest. 2024 Apr; 165(4):950-958.
-
End-of-life practices: An ethical framework for clinicians. Anaesth Crit Care Pain Med. 2023 08; 42(4):101216.
-
The impact of coronavirus disease 2019 on the quality of life and treatment disruption of patients with breast cancer in a multiethnic cohort. Cancer. 2021 11 01; 127(21):4072-4080.
-
Impact of Preexisting Cognitive Impairment and Race/Ethnicity on Functional Outcomes Following Intracerebral Hemorrhage. Stroke. 2021 01; 52(2):603-610.
-
Temporal Evolution and Outcomes of Non-Traumatic Intracerebral Hemorrhage in Hospitalized Patients. J Stroke Cerebrovasc Dis. 2021 Mar; 30(3):105584.
-
Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia. Cancer. 2021 04 01; 127(7):1039-1048.
-
Reflections on Charlie Gard and the Best Interests Standard From Both Sides of the Atlantic Ocean. Pediatrics. 2020 08; 146(Suppl 1):S60-S65.
-
Use and Discontinuation of Insulin Treatment Among Adults Aged 75 to 79 Years With Type 2 Diabetes. JAMA Intern Med. 2019 12 01; 179(12):1633-1641.